Description
BSE announces listing and trading permission for 4,00,000 new equity shares of Novelix Pharmaceuticals Limited effective March 9, 2026, issued on a preferential basis pursuant to conversion of warrants.
Summary
BSE has notified trading members that 4,00,000 new equity shares of Novelix Pharmaceuticals Limited (Scrip Code: 536565) are listed and permitted to trade on the Exchange with effect from Monday, March 9, 2026. These shares were issued on a preferential basis to non-promoters pursuant to the conversion of warrants.
Key Points
- 4,00,000 equity shares of Rs. 10/- each issued at a premium of Rs. 10/- (issue price Rs. 20/-) to non-promoters on a preferential basis.
- Shares issued pursuant to conversion of warrants.
- New shares rank pari-passu with existing equity shares of the company.
- Distribution numbers: 17215001 to 17615000.
- ISIN: INE314I01036.
- All 4,00,000 shares are subject to a lock-in period until September 30, 2026.
Regulatory Changes
No new regulatory changes. This is a standard listing notification under existing BSE listing norms for preferential allotment of securities.
Compliance Requirements
- Trading members are informed to note the listing effective date of March 9, 2026.
- The lock-in on all 4,00,000 shares (Dist. Nos. 17215001 to 17615000) must be observed until September 30, 2026.
Important Dates
- Date of Allotment: January 19, 2026
- Effective Trading Date: March 9, 2026
- Lock-in Expiry: September 30, 2026
Impact Assessment
This listing represents a modest capital increase for Novelix Pharmaceuticals Limited via preferential allotment to non-promoters. The entire lot of 4,00,000 shares is under lock-in until September 30, 2026, which limits immediate free-float impact. Market impact is minimal given the small size of the issue and the lock-in restriction.
Impact Justification
Routine listing of new equity shares from warrant conversion for a single SME-segment company; limited broader market impact.